Endovascular Surgery — Cost, Top Hospitals & Success Rates | MyMedicPlus

Endovascular surgery is a subspecialty of vascular surgery and interventional medicine in which diseases of the arteries and veins are treated through catheter-based, image-guided techniques accessed through small puncture sites in the skin — without the large incisions required for conventional open vascular surgery. A catheter (thin flexible tube) is inserted through the femoral artery in the groin (or other access sites including the brachial artery, radial artery, or popliteal artery) and advanced under fluoroscopic (X-ray), CT, or ultrasound guidance to the target vessel. Through the catheter, therapeutic devices — including stents (metallic mesh tubes that prop open arteries), stent-grafts (covered stents used to exclude aneurysms), balloons (to dilate stenotic vessels), thrombolytic agents (to dissolve thrombus), mechanical thrombectomy devices (to physically remove clot), and embolic agents — are delivered precisely to the target.

Endovascular surgery has transformed the treatment of vascular disease over the past three decades. Major open surgical procedures — including abdominal aortic aneurysm repair (previously requiring a large abdominal incision and aortic clamping), carotid endarterectomy (previously an open neck dissection), and peripheral arterial bypass surgery — are now performed or supplemented endovascularly in the majority of patients, with equivalent or superior short-term outcomes, dramatically reduced perioperative mortality and morbidity, shorter hospitalisation, and faster return to normal activities. Endovascular techniques are particularly advantageous for elderly, frail, or medically complex patients who are high risk for open surgery.

Endovascular surgery is performed by vascular surgeons with endovascular training, interventional radiologists, and in some settings (coronary and carotid intervention), interventional cardiologists and neuroradiologists, in dedicated hybrid operating rooms equipped with fixed or mobile fluoroscopic imaging, intravascular ultrasound, and cone-beam CT capabilities.

Abdominal aortic aneurysm (AAA) — a focal dilatation of the abdominal aorta exceeding 3 cm diameter that risks rupture with catastrophic mortality — is one of the most important endovascular indications. Endovascular aneurysm repair (EVAR) deploys a bifurcated stent-graft system through femoral access to exclude the aneurysm sac from arterial pressure, preventing rupture without the need for aortic clamping or abdominal incision. EVAR has a 30-day mortality of 0.5–1.5% versus 3–5% for open repair, making it the preferred approach for anatomically suitable AAAs. Thoracic aortic aneurysms and dissections are treated by thoracic EVAR (TEVAR) with similar advantages.

Peripheral arterial disease (PAD) — atherosclerotic narrowing of the arteries supplying the legs, causing claudication or critical limb ischaemia — is treated endovascularly by angioplasty (balloon dilation of stenotic arteries), stenting, atherectomy, and drug-eluting balloon angioplasty. Carotid artery stenosis — a major cause of ischaemic stroke — is treated by carotid artery stenting (CAS) as an alternative to carotid endarterectomy (open surgery) in selected patients at high surgical risk. Ischaemic stroke from large vessel occlusion is treated by mechanical thrombectomy — endovascular retrieval of the offending clot from the cerebral artery within a time window of 6–24 hours of stroke onset — one of the most impactful neurological interventions of the modern era. Venous conditions treated endovascularly include deep vein thrombosis (catheter-directed thrombolysis, mechanical thrombectomy), varicose veins (endovenous laser ablation, radiofrequency ablation), and iliac vein compression (May-Thurner syndrome treated by stenting).

Eligibility for endovascular surgery is determined by anatomical criteria (the vascular anatomy must be suitable for the specific endovascular device or technique), clinical indication, medical fitness, and procedural risk-benefit analysis. For EVAR, computed tomography angiography (CTA) planning determines anatomical suitability (aortic neck length, diameter and angulation, iliac access diameter) — approximately 60–70% of AAAs are anatomically suitable for standard EVAR. Custom fenestrated and branched EVAR (FEVAR/BEVAR) extends the technique to complex aneurysms involving the renal and visceral arteries.

For peripheral arterial intervention, the Trans-Atlantic Inter-Society Consensus (TASC) classification guides the choice between endovascular and open revascularisation based on lesion length, number, and severity: short focal stenoses (TASC A–B) are preferentially managed endovascularly; long diffuse disease (TASC C–D) may require bypass surgery for durable results. Medical contraindications to endovascular surgery include severe allergy to iodinated contrast media (manageable with steroid premedication) and severe renal impairment limiting contrast agent use (managed with CO2 angiography or gadolinium contrast alternatives). Patients on anticoagulants require careful periprocedural management.

Endovascular procedures are performed in a vascular suite, hybrid operating room, or catheter laboratory. Standard femoral access is established with a needle puncture and guidewire introduction (Seldinger technique), followed by insertion of a vascular sheath (access port) through which catheters and devices are exchanged. Real-time fluoroscopic imaging using iodinated contrast angiography maps the target vessels and guides device delivery. For EVAR, the bifurcated stent-graft is delivered through large-bore sheaths (18–24 French) introduced through surgical or percutaneous femoral access, expanded within the aortic neck above the aneurysm and in both iliac arteries, and the procedure completed with fluoroscopic confirmation of aneurysm exclusion and absence of endoleak (persistent blood flow into the aneurysm sac).

For peripheral arterial disease, angioplasty uses a balloon catheter inflated within the stenotic segment to displace and compress atheromatous plaque and re-model the arterial wall, restoring luminal calibre. Primary or bailout stenting is performed when angioplasty result is suboptimal (residual stenosis, dissection, elastic recoil). Drug-coated balloons (DCBs) and drug-eluting stents (DES) deliver antiproliferative drugs (paclitaxel, sirolimus) locally to reduce restenosis rates in femoro-popliteal disease. Atherectomy — mechanical removal of plaque using rotational, directional, or laser atherectomy devices — is used for heavily calcified lesions that are poorly responsive to balloon dilation alone.

The primary benefit of endovascular over open vascular surgery is dramatically reduced perioperative morbidity and mortality. The EVAR-1 trial (NEJM, 2004) established that EVAR reduces 30-day mortality to 1.7% versus 4.7% for open repair — a 64% relative risk reduction. Similar advantages are seen for TEVAR versus open thoracic surgery. For elderly and frail patients who are at prohibitive risk for open aortic surgery, EVAR represents the only viable treatment option to prevent aneurysm rupture, whereas historically these patients were managed conservatively with the attendant rupture risk.

For peripheral arterial disease, endovascular revascularisation in claudication improves walking distance by 100–200% in well-selected cases, with primary patency rates of 70–80% for iliac artery interventions at 5 years. Limb salvage rates in critical limb ischaemia are 75–85% at 1 year with endovascular revascularisation, though this population has high mortality from cardiovascular disease. Mechanical thrombectomy for ischaemic stroke has transformed clinical outcomes: the 2015 MR CLEAN, ESCAPE, EXTEND-IA, SWIFT PRIME, and REVASCAT trials all demonstrated significant improvement in functional neurological outcome (modified Rankin Scale 0–2 at 90 days) with mechanical thrombectomy compared to intravenous thrombolysis alone, in patients with large vessel occlusion within 6–24 hours of symptom onset.

Endovascular surgery complications are related to vascular access, contrast media, and device-specific issues. Femoral access site complications (haematoma, pseudoaneurysm, arteriovenous fistula, femoral arterial occlusion) occur in 1–3% of cases and are managed with ultrasound-guided compression, thrombin injection, or surgical repair. Contrast-induced nephropathy — acute kidney injury from iodinated contrast media — is most significant in patients with pre-existing chronic kidney disease (eGFR below 60 mL/min) and is mitigated by hydration protocols, minimising contrast volume, and using iso-osmolar contrast agents.

For EVAR, endoleak — persistent perfusion of the aneurysm sac outside the stent-graft — is the most important long-term complication, classified into types I–V by mechanism. Type I (graft attachment site) and type III (graft junction) endoleaks maintain aneurysm sac pressurisation and require urgent re-intervention. Type II endoleaks (retrograde flow from aortic side branches — lumbar arteries, inferior mesenteric artery) are common (20–30%) and mostly benign, but are surveilled for aneurysm sac enlargement. Stent-graft migration, limb occlusion, and graft infection are long-term EVAR complications requiring surveillance and re-intervention. Arterial embolisation during peripheral intervention can cause distal ischaemia — 'trash foot' from microemboli — in a small proportion of cases.

Recovery after major endovascular procedures (EVAR, TEVAR, carotid stenting) is substantially faster than after open surgery. EVAR patients are typically mobilised on the day of surgery or the following morning, discharged at 2–3 days (versus 7–10 days for open AAA repair), and return to normal activities within 2 weeks. Patients require dual antiplatelet therapy (aspirin + clopidogrel) for 1–4 weeks after carotid stenting, then lifelong aspirin. Peripheral arterial stents require antiplatelet therapy with aspirin indefinitely.

Long-term surveillance is mandatory for EVAR patients: CT angiography at 1 month, 12 months, and annually thereafter (or when endoleak, sac growth, or device migration is suspected) is the standard protocol. Surveillance imaging allows detection of endoleak and aneurysm sac changes that require re-intervention before catastrophic rupture. Patients with peripheral arterial stents are reviewed clinically (ankle brachial index, duplex ultrasound) at 1, 6, and 12 months, then annually. Risk factor modification — smoking cessation (critical for long-term patency and prevention of disease progression), optimal blood pressure control, lipid-lowering with statins, antiplatelet therapy, and regular exercise — is essential for all vascular patients and significantly affects long-term outcomes.

Endovascular surgery costs reflect the expensive specialised devices (stent-grafts, drug-eluting stents, mechanical thrombectomy systems), hybrid operating room infrastructure, and subspecialty expertise involved. In the US, EVAR costs USD 30,000–80,000; carotid artery stenting costs USD 15,000–30,000; and peripheral angioplasty and stenting costs USD 15,000–40,000 depending on complexity. These procedures are covered by Medicare for appropriately indicated conditions with documented vascular disease. In the UK, NHS vascular surgery is free at point of care.

For patients seeking vascular procedures internationally, major teaching hospitals and specialty vascular surgery centres in India, Thailand, and Turkey offer endovascular procedures at 60–75% less than US costs. EVAR at a leading vascular centre in India (AIIMS, All India Institute of Medical Sciences, Apollo, Fortis Malar) costs USD 8,000–15,000 — savings of 70–80% versus US prices, using FDA/CE-approved stent-graft devices. Peripheral angioplasty and stenting costs USD 2,000–5,000 in India; carotid stenting USD 4,000–8,000. Thailand and Turkey offer similar cost profiles. Patients should ensure the treating vascular surgeon and interventional radiologist are subspecialty-trained and that the facility has 24/7 backup for surgical emergencies, including hybrid operating room capability.

Open vascular surgery remains the gold standard for several indications where endovascular approaches have limitations. Open AAA repair is preferred for young, fit patients (under 70) with favourable anatomy, as long-term data from the EVAR-1 trial show that the early mortality advantage of EVAR is not maintained beyond 5–8 years due to EVAR-specific complications (endoleak, device migration) requiring re-interventions — with similar late survival between the two approaches in fit patients. Carotid endarterectomy (open surgical removal of carotid plaque) remains the preferred treatment for symptomatic high-grade carotid stenosis in centres with low surgical complication rates (30-day stroke/death rate under 3%), with carotid stenting reserved for high-risk surgical candidates.

For peripheral arterial disease with multilevel, diffuse disease or below-knee vessels (tibial arteries), surgical bypass — using autologous vein (great saphenous vein or arm vein) as a conduit — provides superior long-term patency compared to endovascular treatment of long-segment occlusions. Best medical therapy — aspirin, statin, ACE inhibitor or ARB, aggressive risk factor modification, and supervised exercise programmes — can significantly improve claudication symptoms and reduce cardiovascular events without revascularisation in patients with mild-moderate claudication, and is recommended as the initial treatment approach before intervention for this group.